Dan Olmstead

Dan Olmstead has a diverse work experience spanning over several companies in the healthcare industry. Dan started their career at Pharmacia (The Upjohn Company) in 1986, where they held various sales, sales management, and managed care positions until 2001.

In 2002, Olmstead joined EyeTel Imaging as the Director of Managed Care until 2004 when they moved to BCI as a National Account Director.

From 2005 to 2013, Olmstead worked at Genzyme in multiple roles. Dan started as a Senior Corporate Account Director, responsible for developing and executing reimbursement strategies for Genzyme Renal. Then, they became a Senior Director Corporate Accounts, leading a team covering regional payors and implementing reimbursement strategies across various therapeutic areas.

In 2013, Olmstead joined Walgreens as the National Accounts Director within their Managed Markets Group, representing all divisions. Dan held this position for a year before moving on to Akebia Therapeutics (formerly Keryx Biopharmaceuticals, Inc.) in 2014. At Akebia Therapeutics, they served as the Vice President for Payer Access, responsible for building and leading market access and reimbursement initiatives in the United States until 2019.

Finally, Olmstead joined Ardelyx, Inc. in 2019 as the Vice President for Market Access, where they are currently responsible for developing the U.S. market access, distribution, and patient services strategy for all Ardelyx products and pipeline assets.

Dan Olmstead attended the University of Michigan from 1981 to 1985, where they earned a Bachelor of General Studies (BGS) degree in Business.